Literature DB >> 3007162

Comparison of enalapril and propranolol in essential hypertension.

B A van Schaik, G G Geyskes, N Kettner, P Boer, E J Mees.   

Abstract

In 40 patients with essential hypertension, enalapril was compared with propranolol as an antihypertensive agent in a double-blind study. The patients were randomly given either enalapril 5-10-20 mg bid or propranolol 40-80-120 mg bid in a treatment consisting of step-by-step increases in dosage. When the diastolic blood pressure remained greater than 90 mm Hg on the highest dosage, hydrochlorothiazide was added. Both enalapril and propranolol reduced blood pressure, although the patients tended to achieve lower blood pressures while on enalapril. More patients on propranolol required additional diuretic therapy than patients on enalapril. Propranolol reduced heart rate; with enalapril there were no changes in heart rate. Both drugs increased serum potassium and urea. Plasma renin substrate was reduced by enalapril, but raised by propranolol. Enalapril increased plasma renin activity and angiotensin I, while propranolol reduced both. Converting enzyme activity was lowered with enalapril but was unchanged with propranolol. Both drugs reduced angiotensin II. Plasma aldosterone concentration was more suppressed with propranolol than with enalapril.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3007162     DOI: 10.1007/bf00635885

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  20 in total

1.  Antihypertensive effect of the new oral angiotensin converting enzyme inhibitor "MK-421".

Authors:  H Gavras; J Biollaz; B Waeber; H R Brunner; I Gavras; R O Davies
Journal:  Lancet       Date:  1981-09-12       Impact factor: 79.321

Review 2.  Angiotensin-converting enzyme inhibitors: past, present, and bright future.

Authors:  C R Edwards; P L Padfield
Journal:  Lancet       Date:  1985-01-05       Impact factor: 79.321

3.  Blood and extracellular fluid volume in patients with Bartter's syndrome.

Authors:  P Boer; R J Hené; H A Koomans; M G Nieuwenhuis; G G Geyskes; E J Mees
Journal:  Arch Intern Med       Date:  1983-10

4.  Antihypertensive efficacy of once daily MK-521, a new nonsulfhydryl angiotensin-converting enzyme inhibitor.

Authors:  H H Rotmensch; P H Vlasses; B N Swanson; J D Irvin; K E Harris; D G Merrill; R K Ferguson
Journal:  Am J Cardiol       Date:  1984-01-01       Impact factor: 2.778

Review 5.  Captopril: a preliminary review of its pharmacological properties and therapeutic efficacy.

Authors:  R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1980-12       Impact factor: 9.546

6.  Enalapril in essential hypertension: a comparative study with propranolol. Enalapril in Hypertension Study Group (UK).

Authors: 
Journal:  Br J Clin Pharmacol       Date:  1984-07       Impact factor: 4.335

7.  Optimized assay for serum angiotensin-converting enzyme activity.

Authors:  P L Hurst; C J Lovell-Smith
Journal:  Clin Chem       Date:  1981-12       Impact factor: 8.327

8.  Cardiac and hormonal effects of enalapril in hypertension.

Authors:  S Morioka; G Simon; J N Cohn
Journal:  Clin Pharmacol Ther       Date:  1983-11       Impact factor: 6.875

9.  Enalapril and autonomic reflexes and exercise performance.

Authors:  J L Reid; J A Millar; B C Campbell
Journal:  J Hypertens Suppl       Date:  1983-10

10.  Cardiac and haemodynamic effects of enalapril.

Authors:  F M Fouad; R C Tarazi; E L Bravo
Journal:  J Hypertens Suppl       Date:  1983-10
View more
  2 in total

1.  Changes in haemodynamics and body fluid volume due to enalapril in patients with essential hypertension on chronic diuretic therapy.

Authors:  B A van Schaik; G G Geyskes; P Boer; E J Dorhout Mees
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

2.  Comparison of the renal effects of angiotensin converting enzyme inhibitor and calcium antagonist in hypertensive type 2 (non-insulin-dependent) diabetic patients with microalbuminuria: a randomised controlled trial.

Authors:  T Baba; S Murabayashi; K Takebe
Journal:  Diabetologia       Date:  1989-01       Impact factor: 10.122

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.